Download PDF
Semin Thromb Hemost
DOI: 10.1055/s-0044-1782518
Review Article

Prophylactic Treatment of Children with Hemophilia in Sweden

Rolf Ljung
1   Department of Clinical Sciences Lund – Pediatrics, Lund University, Lund, Sweden
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Hemophilia A/B are caused by deficiency or lack of coagulation factors VIII (FVIII) or factor IX (FIX), respectively, in plasma. A person with hemophilia develops bleeding in the joints and muscles at an early age, which, if left untreated, leads to early arthropathy. Preventive treatment can be achieved by regular (prophylactic) administration of FVIII/FIX. In 1958, this was implemented on a small scale in Sweden with FVIII in patients with severe hemophilia A, and in those with hemophilia B in 1972 when FIX became available. However, there were problems with human immunodeficiency virus and hepatitis infection from contaminated blood products. In the 1990s, recombinant FVIII and FIX concentrates were introduced. The major remaining problems then were the development of inhibitors, and the need for a venous route for the injections in very young children. High-titer inhibitors were treated by immune tolerance induction according to a modified model of the original Bonn high-dose protocol. A central venous line, i.e., Port-A-Cath, has enabled early prophylaxis in many children with poor venous access and has enabled the early start of home treatment with adequate injection frequency. Scoring systems for X-rays, magnetic resonance imaging, and function of joints were developed early in Sweden and have been widely disseminated worldwide, partly with modifications. Extended half-life products with half-life increased three to five times have been developed, which can provide superior bleed protection when dosed once-weekly and can maintain therapeutic trough levels when administered less frequently. The ultimate prophylaxis therapy in the future may be gene therapy.

Keywords

hemophilia A - hemophilia B - pediatric - prophylaxis - factor VIII - factor IX


Publication History

Article published online:
18 March 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; (Suppl. 77) 77 , 3–132
    PubMedGoogle Scholar
  • 2 Blomback M, Nilsson IM. Treatment of hemophilia A with human antihemophilic globulin. Acta Med Scand 1958; 161 (04) 301-321
    CrossrefPubMedGoogle Scholar
  • 3 Nilsson IM, Blombäck M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol 1970; 34: 111-124
    PubMedGoogle Scholar
  • 4 Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65 (02) 129-135
    CrossrefPubMedGoogle Scholar
  • 5 Iorio A, Keepanasseril A, Foster G. et al; WAPPS-Hemo co-investigator network. Development of a web-accessible population pharmacokinetic service-hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc 2016; 5 (04) e239
    CrossrefPubMedGoogle Scholar
  • 6 Collins PW. Personalized prophylaxis. Haemophilia 2012; 18 (Suppl. 04) 131-135
    CrossrefPubMedGoogle Scholar
  • 7 Schimpf K, Baumann P. A controlled study of long-term treatment of haemophilia B on an out-patient basis (author's transl) [in German]. Dtsch Med Wochenschr 1976; 101 (07) 233-238 Die ambulante Dauerbehandlung der Hamophilie B. Eine kontrollierte Studie.
    PubMedGoogle Scholar
  • 8 Aronstam A, Arblaster PG, Rainsford SG. et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33 (01) 81-90
    CrossrefPubMedGoogle Scholar
  • 9 Verma SP, Dutta TK, Mahadevan S. et al. A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country. Haemophilia 2016; 22 (03) 342-348
    CrossrefPubMedGoogle Scholar
  • 10 Wu R, Luke KH, Poon MC. et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011; 17 (01) 70-74
    CrossrefPubMedGoogle Scholar
  • 11 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (01) 25-32
    CrossrefPubMedGoogle Scholar
  • 12 Berntorp E, Hansson BG, Böttiger B. et al. HIV seroconversion in Swedish haemophiliacs: relation to type and dosage of factor concentrate. Eur J Haematol 1987; 38 (03) 256-260
    CrossrefPubMedGoogle Scholar
  • 13 Knobe KE, Sjörin E, Tengborn LI, Petrini P, Ljung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr 2002; 91 (08) 910-914
    CrossrefPubMedGoogle Scholar
  • 14 Gouw SC, van der Bom JG, Ljung R. et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (03) 231-239
    CrossrefPubMedGoogle Scholar
  • 15 Peyvandi F, Mannucci PM, Garagiola I. et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374 (21) 2054-2064
    CrossrefPubMedGoogle Scholar
  • 16 Mårtensson A, Letelier A, Halldén C, Ljung R. Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations. Haemophilia 2016; 22 (03) 440-445
    CrossrefPubMedGoogle Scholar
  • 17 Male C, Andersson NG, Rafowicz A. et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 2021; 106 (01) 123-129
    CrossrefPubMedGoogle Scholar
  • 18 Gouw SC, van den Berg HM, Fischer K. et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121 (20) 4046-4055
    CrossrefPubMedGoogle Scholar
  • 19 Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2 (8044): 933
    CrossrefPubMedGoogle Scholar
  • 20 Ljung RCR. How I manage patients with inherited haemophilia A and B and factor inhibitors. Br J Haematol 2018; 180 (04) 501-510
    CrossrefPubMedGoogle Scholar
  • 21 Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia 1999; 5 (01) 32-39
    CrossrefPubMedGoogle Scholar
  • 22 Lindvall K, von Mackensen S, Elmståhl S. et al. Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatr Blood Cancer 2014; 61 (04) 706-711
    CrossrefPubMedGoogle Scholar
  • 23 Petrini P. How to start prophylaxis. Haemophilia 2003; 9 (Suppl. 01) 83-85 , discussion 86–87
    CrossrefPubMedGoogle Scholar
  • 24 Feldman BM, Pai M, Rivard GE. et al; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4 (06) 1228-1236
    CrossrefPubMedGoogle Scholar
  • 25 Ljung R, Petrini P, Lindgren AK, Berntorp E. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992; 81 (11) 918-920
    CrossrefPubMedGoogle Scholar
  • 26 Ljung R. Central venous catheters in children with haemophilia. Blood Rev 2004; 18 (02) 93-100
    CrossrefPubMedGoogle Scholar
  • 27 Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; (149) 153-159
    PubMedGoogle Scholar
  • 28 Pettersson H, Nilsson IM, Hedner U, Noréhn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70 (04) 565-570
    CrossrefPubMedGoogle Scholar
  • 29 Soreff J, Blombäck M. Arthropathy in children with severe hemophilia A. Acta Paediatr Scand 1980; 69 (05) 667-673
    CrossrefPubMedGoogle Scholar
  • 30 Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004; 10 (04) 383-389
    CrossrefPubMedGoogle Scholar
  • 31 Lundin B, Ljung R, Pettersson H. European Paediatric Network for Haemophilia Management (PEDNET). MRI scores of ankle joints in children with haemophilia–comparison with clinical data. Haemophilia 2005; 11 (02) 116-122
    CrossrefPubMedGoogle Scholar
  • 32 Lundin B, Baghaei F, Holmström M. et al. Haemophilia A and B - evaluation of the Swedish prophylactic regimen by magnetic resonance imaging. Haemophilia 2023; 29 (01) 193-198
    CrossrefPubMedGoogle Scholar
  • 33 Hill FG, Ljung R. European Paediatric Network for Haemophilia Management. Third and fourth Workshops of the European Paediatric Network for Haemophilia Management. Haemophilia 2003; 9 (02) 223-228
    CrossrefPubMedGoogle Scholar
  • 34 Feldman BM, Funk SM, Bergstrom BM. et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63 (02) 223-230
    CrossrefPubMedGoogle Scholar
  • 35 Andersson NG, Auerswald G, Barnes C. et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol 2017; 179 (02) 298-307
    CrossrefPubMedGoogle Scholar
  • 36 Petrini P, Seuser A. Haemophilia care in adolescents–compliance and lifestyle issues. Haemophilia 2009; 15 (Suppl. 01) 15-19
    CrossrefPubMedGoogle Scholar
  • 37 Lindvall K, Astermark J, Björkman S. et al; Clinical Trial Randomized Controlled Trial. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18 (06) 855-859
    CrossrefPubMedGoogle Scholar
  • 38 Hart DP, Matino D, Astermark J. et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol 2022; 13: 20 406207221085202
    CrossrefPubMedGoogle Scholar
  • 39 Cooley B, Broze Jr GJ, Mann DM, Lin FC, Pedersen LG, Stafford DW. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model. Blood 2019; 133 (22) 2445-2451
    CrossrefPubMedGoogle Scholar
  • 40 Demers M, Aleman MM, Kistanova E, Peters R, Salas J, Seth Chhabra E. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII. J Thromb Haemost 2022; 20 (07) 1674-1683
    CrossrefPubMedGoogle Scholar
  • 41 von Drygalski A, Chowdary P, Kulkarni R. et al; XTEND-1 Trial Group. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388 (04) 310-318
    CrossrefPubMedGoogle Scholar
  • 42 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
    CrossrefPubMedGoogle Scholar
  • 43 Pasi KJ, Rangarajan S, Georgiev P. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377 (09) 819-828
    CrossrefPubMedGoogle Scholar
  • 44 Waters EK, Sigh J, Friedrich U, Hilden I, Sørensen BB. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia 2017; 23 (05) 769-776
    CrossrefPubMedGoogle Scholar
  • 45 Polderdijk SG, Adams TE, Ivanciu L, Camire RM, Baglin TP, Huntington JA. Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood 2017; 129 (01) 105-113
    CrossrefPubMedGoogle Scholar
  • 46 Symington E, Rangarajan S, Lester W. et al. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment. Haemophilia 2024; (e-pub ahead of print) DOI: 10.1111/hae.14936.
    CrossrefPubMedGoogle Scholar
  • 47 Klamroth R, Bonner A, Gomez K. et al. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B. Haemophilia 2024; 30 (01) 75-86
    CrossrefPubMedGoogle Scholar